The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence

BACKGROUND: Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+ patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hicks, David G, Janarthanan, Bagi R, Vardarajan, Ramya, Kulkarni, Swati A, Khoury, Thaer, Dim, Daniel, Budd, G Thomas, Yoder, Brian J, Tubbs, Raymond, Schreeder, Marshall T, Estopinal, Noel C, Beck, Rodney A, Wang, Yanling, Ring, Brian Z, Seitz, Robert S, Ross, Douglas T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859753/
https://www.ncbi.nlm.nih.gov/pubmed/20307320
http://dx.doi.org/10.1186/1471-2407-10-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859753/
https://www.ncbi.nlm.nih.gov/pubmed/20307320
http://dx.doi.org/10.1186/1471-2407-10-108

Ejemplares similares